[HTML][HTML] Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR

…, K Yoshimori, T Harada, T Ogura… - … England Journal of …, 2010 - Mass Medical Soc
Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib…

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double …

…, H Sakai, K Inoue, C Kitagawa, T Ogura… - The lancet …, 2009 - thelancet.com
Background Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT 3 )-receptor
antagonist that has shown better efficacy than ondansetron and dolasetron in preventing …

Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases

…, DL Hotchkin, AM Nambiar, T Ogura… - European …, 2018 - Eur Respiratory Soc
Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs)
may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with …

Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival

…, M Suga, H Taniguchi, Y Kondoh, T Ogura… - American journal of …, 2008 - atsjournals.org
Rationale: Patients with a clinicopathological diagnosis of idiopathic pulmonary fibrosis (IPF)
may have typical findings of usual interstitial pneumonia (UIP) on computed tomography (…

Determination of damage-free crystal structure of an X-ray–sensitive protein using an XFEL

…, M Yabashi, T Ishikawa, M Yamamoto, T Ogura… - Nature …, 2014 - nature.com
We report a method of femtosecond crystallography for solving radiation damage–free crystal
structures of large proteins at sub-angstrom spatial resolution, using a large single crystal …

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

…, M Kaye, U Costabel, I Glaspole, T Ogura… - The Lancet …, 2019 - thelancet.com
Background The efficacy and safety of nintedanib, an intracellular tyrosine kinase inhibitor,
in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo-…

Catalytic mechanism of water oxidation with single-site ruthenium–heteropolytungstate complexes

…, T Suenobu, S Yamaguchi, T Ogura… - Journal of the …, 2011 - ACS Publications
Catalytic water oxidation to generate oxygen was achieved using all-inorganic mononuclear
ruthenium complexes bearing Keggin-type lacunary heteropolytungstate, [Ru III (H 2 O)SiW …

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

T Ogura, H Taniguchi, A Azuma, Y Inoue… - European …, 2015 - Eur Respiratory Soc
A randomised, double-blind, phase II, dose escalation trial was conducted to assess the
safety, tolerability and pharmacokinetics of the tyrosine kinase inhibitor nintedanib, alone and …

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

…, R Kato, J Tanizaki, K Tanaka, M Takeda, T Ogura… - Clinical Cancer …, 2020 - AACR
Ogura reports receiving commercial research grants from Boehringer Ingelheim Japan
Inc., and The Mental Health Okamoto Memorial Foundation, and reports receiving speakers …

Mononuclear copper (II)− superoxo complexes that mimic the structure and reactivity of the active centers of PHM and DβM

A Kunishita, M Kubo, H Sugimoto, T Ogura… - Journal of the …, 2009 - ACS Publications
Mononuclear copper(II)−superoxo complexes 2 X −OO • having triplet (S = 1) ground states
were obtained via reaction of O 2 with the copper(I) starting materials 1 X supported by …